Inclusion Criteria:

          -  Eligible are all CD30+ malignant lymphoma, meaning lymphoma subtypes such as Hodgkin
             lymphomas, angioimmunoblastic T-cell lymphomas (AITL), anaplastic ALK+ T-cell
             lymphomas, Sézary-syndrome, but also all other malignant CD30+ lymphoma types.

          -  Patients must be in first or second remission or second chemosensitive relapse and
             patients must be planned to undergo subsequent consolidation with standard high-dose
             chemotherapy with autologous stem cell transplantation.

          -  Patients must be aged 18-75 years, and must have given voluntary written informed
             consent.

          -  Negative pregnancy test (urine or serum) within 14 days prior to registration for all
             women of childbearing potential. Patients of childbearing potential must implement two
             effective contraceptive measures (hormonal treatment p.o. or i.m., intra uterine
             surgical devices, or latex condoms) to avoid pregnancy from the time of signing
             informed consent and for additional 12 months. No pregnant or lactating patients are
             allowed.

          -  Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to
             practice effective barrier contraception during the entire study period and through 12
             months after the last dose of study drug, or agrees to completely abstain from
             heterosexual intercourse.

          -  Absolute neutrophil count ≥ 1,500/µL unless there is known hematologic/solid tumor
             marrow involvement.

          -  Platelet count ≥ 75,000/ µL unless there is known marrow involvement of the disease.

          -  Total bilirubin must be < 1.5 x the upper limit of the normal (ULN) unless the
             elevation is known to be due to Gilbert syndrome.

          -  ALT or AST must be < 3 x the upper limit of the normal range. AST and ALT may be
             elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the
             presence of hematologic/solid tumor in liver.

          -  Serum creatinine must be < 2.0 mg/dL and/or calculated creatinine clearance > 40
             mL/minute (Cockcroft-Gault).

          -  Hemoglobin must be ≥ 8g/dL.

        Exclusion Criteria:

          -  Patients considered to be not fit for autologous stem cell transplantation (ASCT).

          -  Patients with other serious medical condition that interfere with the completion of
             treatment according to this protocol or that would impair tolerance to therapy or
             prolong hematological recovery. Patients with seropositivity for HIV or for Hepatitis
             B and C are not excluded from this study if they are otherwise considered fit for
             ASCT.

          -  Symptomatic neurologic disease compromising normal activities of daily living or
             requiring medications. Any sensory or motor peripheral neuropathy greater than or
             equal to Grade 2.

          -  Known history of any of the following cardiovascular conditions: Myocardial infarction
             within 2 years of registration, New York Heart Association (NYHA) Class III or IV
             heart failure (See Appendix 5). Evidence of current uncontrolled cardiovascular
             conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities, Recent evidence (within 6 months before first dose of study drug) of a
             left-ventricular ejection fraction <50%.

          -  Patients that have not completed any prior treatment chemotherapy and/or other
             investigational agents within at least 5 half-lives of last dose of that prior
             treatment. Known hypersensitivity to recombinant proteins, murine proteins, or to any
             excipient contained in the drug formulation of Brentuximab Vedotin.

          -  Acute uncontrolled infection.

          -  Relevant co-existing disease excluding a treatment according to protocol.

          -  Concurrent malignant disease with the exception of basalioma/spinalioma of the skin,
             early-stage cervix carcinoma, or early-stage prostate cancer. • Previous treatment for
             other malignancies (not listed above) must have been terminated at least 24 months
             before registration and no evidence of active disease must be documented since then.

          -  Lack of patient cooperation to allow study treatment as outlined in this protocol.

          -  Pregnant or lactating female patients.

          -  Major coagulopathy or bleeding disorder.

          -  Major surgery less than 30 days before start of treatment.